The Ipamorelin mechanism of action explains one step.

A receptor is a protein that responds to particular chemical signals. Ipamorelin activates the ghrelin receptor. That can lead the pituitary, a small gland near the brain, to release growth hormone. It encourages release rather than adding growth hormone directly.

The early experiments measured this activity in animals and animal cells. The name for a substance that triggers release is secretagogue. You don’t need to remember the word to follow the finding: researchers saw growth hormone rise.

In the animal experiments, Ipamorelin didn’t produce the same rise in ACTH and cortisol as some older peptides. These are hormones involved in the stress response. That narrower hormone pattern is what selective describes here.

It’s an interesting distinction. It doesn’t mean nothing else happens in the body, or that side effects have been ruled out. I keep the word beside the animal comparison that earned it.

If a claim goes from “selective release” straight to “better recovery”, I pause at the gap. Did the study measure recovery? A good explanation of the first step can leave the last step untested.

The healthy-volunteer study used infusions into a vein. Researchers measured Ipamorelin in the blood and a short-lived rise in growth hormone in men. That adds a human observation to the animal work.

It wasn’t a sleep or workout-recovery trial. The FDA review also didn’t find human data on blood levels or hormone response after the proposed injection under the skin. A result from an infusion doesn’t fill that gap.

I look for both the outcome and the route when I read a claim. Otherwise a real finding can end up answering a question the researchers never asked.